Back to Search
CHRISTOPHER RICHMAN, LDO
LDO
Optician
NPI: 1467143339Individual
Specialties, Licenses & Credentials
OpticianPrimary
Technician/Technologist — Optician
Code: 156FX1800X
60922169(WA)
Research & Publications (20)
Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
PMID 16965873·Int J Radiat Oncol Biol Phys·2006
4-observational
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
PMID 16203820·Clin Cancer Res·2005
8-other
Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
PMID 16203816·Clin Cancer Res·2005
7-preclinical
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
PMID 16115934·Clin Cancer Res·2005
3-trial
Inactivation of FGF8 in early mesoderm reveals an essential role in kidney development.
PMID 16049111·Development·2005
7-preclinical
Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
PMID 15937317·J Nucl Med·2005
8-other
Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature.
PMID 15054816·Am J Hematol·2004
5-case
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
PMID 14506192·Clin Cancer Res·2003
8-other
Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
PMID 12804049·Cancer Biother Radiopharm·2003
8-other
Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms.
PMID 12586770·Endocrinology·2003
7-preclinical
Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation.
PMID 12473136·Transfusion·2002
5-case
Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia.
PMID 12463601·Int J Hematol·2002
5-case
Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial.
PMID 12111764·Am J Hematol·2002
3-trial
Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.
PMID 11410491·Clin Cancer Res·2001
3-trial
Systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism.
PMID 11356715·Endocrinology·2001
7-preclinical
Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies.
PMID 11255079·Crit Rev Oncol Hematol·2001
6-review
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
PMID 11251003·J Clin Oncol·2001
8-other
Postnatal and pubertal skeletal changes contribute predominantly to the differences in peak bone density between C3H/HeJ and C57BL/6J mice.
PMID 11204439·J Bone Miner Res·2001
7-preclinical
Evidence that IGF-binding protein-5 functions as a growth factor.
PMID 11134182·J Clin Invest·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1860 E MAIN ST
OTHELLO, WA 99344 - Phone
- (509) 346-6005
Quick Facts
- NPI
- 1467143339
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile